论文部分内容阅读
目的探讨乙型肝炎病毒(HBV)感染与弥漫大B细胞淋巴瘤(DLBCL)预后的相关性。方法选取乙型肝炎表面抗原(HBsAg)阳性和HBsAg阴性的初治DLBCL患者各60例,均给予化疗,比较分析两组患者化疗期间的肝功能以及随访2年后的无进展生存时间(PFS)和总生存时间(OS)。结果 HBsAg阳性组和HBsAg阴性组患者化疗期间的肝功能损害发生率分别为66.0%和40.0%,差异有统计学意义(P<0.05)。HBsAg阳性组患者的PFS为(16.1±3.2)个月,PFS率为70.0%,OS率为85.0%;HBsAg阴性组患者的PFS为(17.3±4.1)个月,PFS率为73.0%,OS率为88.0%,两组差异无统计学意义(P>0.05)。结论 HBV感染与DLBCL患者的预后无关,但合并HBV感染会增加DLBCL患者在化疗期间肝功能损害的发生率。
Objective To investigate the relationship between hepatitis B virus (HBV) infection and the prognosis of diffuse large B cell lymphoma (DLBCL). Methods Sixty patients with newly diagnosed DLBCL who were positive for HBsAg and negative for HBsAg were enrolled in this study. All patients were given chemotherapy. The liver function during chemotherapy and the progression-free survival time (PFS) after 2 years of follow-up were compared. And total survival time (OS). Results The incidence of liver damage during chemotherapy was 66.0% and 40.0% in HBsAg positive patients and HBsAg negative patients, respectively. The difference was statistically significant (P <0.05). The PFS of HBsAg-positive patients was (16.1 ± 3.2) months, the PFS rate was 70.0% and the OS rate was 85.0%. The HBsAg-negative patients had PFS of (17.3 ± 4.1) months and PFS rate of 73.0% 88.0%, no significant difference between the two groups (P> 0.05). Conclusion HBV infection has no relationship with the prognosis of patients with DLBCL, but the combination of HBV infection will increase the incidence of liver dysfunction in patients with DLBCL during chemotherapy.